Page 1 of 1
Hindsight
Posted: Thu Jun 18, 2020 1:39 am
by Gwikley
Looking at the stats for new cases of MF in the US annually: 16.5 -18K per.
Wondering how JnJ saw Imetelstat as a "Billion dollar" pipeline drug.
Re: Hindsight
Posted: Thu Jun 18, 2020 6:09 am
by biopearl123
Gwickley, not sure what you mean but both Janssen and Dr. Scarlett estimate potential income in MF to be in that range. Also both kmall and Dr. Mascarenhas feel the actual numbers of cases are underestimated. bp
Re: Hindsight
Posted: Thu Jun 18, 2020 2:05 pm
by CKTC
Incyte’s Jakafi (ruxolitinib) did $1.7 billion in annual sales in 2019, principally in one indication - myelofibrosis. Incyte expects Jakafi to become a $3 billion brand eventually. There are no approved treatments for refractory myelofibrosis. This market will be lucrative for Geron if imetelstat is approved, and the company’s estimate of $1.5 billion in potential worldwide revenues is not unreasonable.